机器学习模型的阿尔茨海默病的频谱使用血液测试的阿尔茨海默病
Nicola Walter Falasca1, Antonio Ferretti1,2,3, Alberto Granzotto1,4
1Department of Neuroscience, Imaging, and Clinical Sciences G. d'Annunzio University of Chieti-Pescara Chieti Italy.
Alzheimer's & dementia (Amsterdam, Netherlands)
|December 12, 2025
概括
分析血液测试的机器学习模型可以检测认知能力下降的早期迹象. 关键的预测特征包括氨基酸,脂蛋白和脂肪酸,为诊断阿尔茨海默病和轻度认知障碍提供了一种新方法.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 机器学习 机器学习
背景情况:
- 传统的阿尔茨海默病 (AD) 诊断使用脑脊液和血生物标志物,如粉样β和酸化.
- 这些已确定的生物标志物代表了一种有限的,以假设为导向的疾病拦截方法.
研究的目的:
- 调查血液生物标志物的数据驱动分析的潜力,以检测临床前认知衰退.
- 与健康对照组 (HC) 相比,确定关键的血液分析物和预测稳定轻度认知障碍 (sMCI) 和AD的特征.
主要方法:
- 在人口统计数据,阿波利波蛋白E (APOE) ε4基因和82个血液生物标志物的应用数据驱动分析.
- 利用来自HC,sMCI和AD患者组的数据的机器学习分类算法.
主要成果:
- 在两组中发现了与胆固醇相关的分析物的显著差异.
- APOE ε4,氨基酸,脂蛋白和脂肪酸是ML分类中最有影响力的特征.
- 糖解代谢产物,氨基酸和脂肪酸有效地将sMCI和AD与HC区分开来.
结论:
- 与痴呆症相关的系统性变化可以在临床前阶段使用血液生物标志物和ML模型检测到.
- 血液中的代谢和炎症生物标志物可以作为认知健康评估的生物签名.
关键词:
阿波利波蛋白E (APOE) ε4等位基因与胆固醇相关的分析剂.循环的外围生物标志物脂肪酸 脂肪酸 脂肪酸 脂肪酸与葡萄糖溶解相关的代谢物.轻度认知障碍 (MCI) 是一种轻度认知障碍.监督支持矢量机器 (SVM) 算法更多相关视频
06:19Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
2.7K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752